Rank |
Status |
Study |
1 |
Unknown †
|
Preventing ICU Subsyndromal DELIRIUM Conversion to DELIRIUM With Haloperidol
Condition: |
Subsyndromal DELIRIUM |
Interventions: |
Drug: Haloperidol decanoate; Drug: Placebo |
Outcome Measures: |
Conversion from subsyndromal DELIRIUM to DELIRIUM during the period of study drug administration (up to 10 days).; The number of hours spent agitated (SAS >/=5) as percent of time study drug administered (up to 10 days).; Duration of mechanical ventilation.; Clinically significant QTc interval prolongation (≥ 500 msec or an increase of more than 60msec above baseline); Extrapyramidal effects (as evidenced by a positive Simpson-Angus Scale Score); The number of hours spent excessively sedated (SAS ≤ 2) as a percent of time study drug administered (up to 10 days).; Cognition, incidence of anxiety, incidence of depressive symptoms, quality of life (ie., functional status and emotional well being)and sleep quality. |
|
2 |
Recruiting
|
Incidence, Long- Term Outcome and Factor Related to Non- Cardiac Postoperative DELIRIUM in Elderly Patients
Condition: |
Postoperative DELIRIUM |
Intervention: |
|
Outcome Measures: |
Incidence of postoperative DELIRIUM; Factor related to postoperative DELIRIUM; Long-term outcomes (cognitive impairment) |
|
3 |
Recruiting
|
Efficacy of Quetiapine for Pediatric DELIRIUM
Condition: |
DELIRIUM |
Interventions: |
Drug: quetiapine; Other: Placebo |
Outcome Measures: |
Time to first resolution of DELIRIUM; Total ICU days with DELIRIUM |
|
4 |
Recruiting
|
Effects of Prophylactic Use of Haloperidol in Critically Ill Patients With a High Risk for DELIRIUM
Condition: |
DELIRIUM |
Intervention: |
Drug: Haloperidol |
Outcome Measures: |
All cause mortality; DELIRIUM incidence during ICU stay; Number of DELIRIUM free days; DELIRIUM related outcome during ICU stay; Determining efficacy in different risk groups; Side effects of haloperidol prophylaxis during prophylactic treatment |
|
5 |
Recruiting
|
Prospective Randomised Controlled Trial of DELIRIUM Management by Geriatric Medicine Versus General Medicine
Condition: |
DELIRIUM |
Intervention: |
Other: Geriatric assessment review |
Outcome Measures: |
Return home rate; Survival; Percentage residing at home; Hospital complications of DELIRIUM |
|
6 |
Recruiting
|
Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of DELIRIUM
Condition: |
DELIRIUM |
Interventions: |
Drug: Quetiapine; Drug: Haloperidol; Drug: Placebo |
Outcome Measures: |
Time to first resolution of DELIRIUM; Days in DELIRIUM during the study; Duration of DELIRIUM; Severity of DELIRIUM (highest Nu-DESC score, mean episode Nu-DESC score); ICU and hospital mortality; ICU and hospital length of stay; Length of mechanical ventilation; Time spent deeply sedated (RASS <3); Episodes of subject-initiated device removal; Use of haloperidol therapy (including total dose in haloperidol equivalents during the study, number of doses, number of days of therapy, use of rescue IV haloperidol); Average daily and maximum total antipsychotic drug dose in haloperidol equivalents; Duration of study drug administration; Use of benzodiazepines; Use of opioids; QTc prolongation; Extrapyramidal symptoms; Neuroleptic malignant syndrome |
|
7 |
Unknown †
|
Risperidone and Zotepine in the Treatment of DELIRIUM
Condition: |
DELIRIUM |
Intervention: |
Drug: Risperidone and Zolpidem for DELIRIUM |
Outcome Measures: |
DELIRIUM rating scale; MMSE, CGI, side effect profile, HRV |
|
8 |
Recruiting
|
Prevention of DELIRIUM After Bone Marrow Transplantation
Condition: |
DELIRIUM |
Interventions: |
Device: Bright light therapy; Device: Sham light |
Outcome Measures: |
Incidence of DELIRIUM (Time to the development of DELIRIUM based on meeting criteria on the DELIRIUM Rating Scale and/or Memorial DELIRIUM Assessment Scale); Length and severity of DELIRIUM episodes; Average dose of antipsychotic medications required to manage DELIRIUM; Hospital length of stay; Complications (falls, aspiration, infections, nutritional deficits) |
|
9 |
Recruiting
|
Pharmacological Management of DELIRIUM
Conditions: |
DELIRIUM; Cognitive Impairment |
Interventions: |
Behavioral: Reduced exposure to anticholinergics; Procedure: Reduced exposure to benzodiazepines; Drug: Haloperidol; Procedure: Usual care |
Outcome Measures: |
DELIRIUM severity, days free of DELIRIUM and coma, measured by DRS-R-98, CAM-ICU, and RASS; Length of stay; Mortality; Hospital-acquired complications related to DELIRIUM or DELIRIUM management |
|
10 |
Recruiting
|
Early Nurse Detection and Management of DELIRIUM
Condition: |
DELIRIUM Superimposed on Dementia |
Intervention: |
Behavioral: END-DSD |
Outcome Measures: |
Severity of DELIRIUM; Inappropriate CNS-Active Medication Use; Nurse Detection of DELIRIUM; DELIRIUM Duration |
|
11 |
Unknown †
|
Impact of Impaired Cerebral Autoregulation on Postoperative DELIRIUM in Elderly Patients Undergoing Spine Surgery
Condition: |
DELIRIUM |
Intervention: |
|
Outcome Measures: |
Incidence of post-operative DELIRIUM in elderly patients undergoing spine surgery at Johns Hopkins Hospital; Severity of postoperative DELIRIUM, using DELIRIUM Rating Scale-Revised-1998, in elderly patients undergoing spine surgery. |
|
12 |
Recruiting
|
Anesthesia-analgesia Methods and Postoperative DELIRIUM
Conditions: |
DELIRIUM; Postoperative Complications |
Intervention: |
Other: Combined Epi-GA/PCEA |
Outcome Measures: |
Incidence of postoperative DELIRIUM; Incidence of postoperative complications; 30-day mortality; VAS pain score; Duration of hospital stay after surgery; Daily prevalence of postoperative DELIRIUM |
|
13 |
Recruiting
|
Impact of a Multifaceted Program to Prevent Postoperative DELIRIUM in the Elderly
Condition: |
Postoperative DELIRIUM |
Intervention: |
Behavioral: Multifaceted prevention program HELP(Hospital Elder Life Program) |
Outcome Measures: |
Postoperative DELIRIUM rate within 7 days after surgery; Mean DELIRIUM intensity within 7 days after surgery; Length of hospital stay; Postoperative complications 30 days after surgery incidence; Mortality 6 months after surgery; Feasibility of the multidisciplinary prevention program |
|
14 |
Recruiting
|
Does Nightly Dexmedetomidine Improve Sleep and Reduce DELIRIUM in ICU Patients?
Conditions: |
Sleep Deprivation; DELIRIUM |
Interventions: |
Drug: Dexmedetomidine; Other: Placebo |
Outcome Measures: |
Development of DELIRIUM; Development of subsyndromal DELIRIUM |
|
15 |
Recruiting
|
Instruments for DELIRIUM Assessment Regarding to Analgesia Sedation and Ventilator Status
Condition: |
DELIRIUM |
Intervention: |
|
Outcome Measures: |
Sensitivity of the DELIRIUM screening/diagnosing tool "Confusion Assessment Method for the ICU (CAM-ICU)" regarding sedation and ventilator status.; Sensitivity of the DELIRIUM-screening tool "Intensive-Care DELIRIUM Screening Checklist(ICDSC)" regarding sedation and ventilator status.; Sensitivity of the DELIRIUM screening tool "Nursing DELIRIUM Screening Scale (Nu-DESC)" regarding sedation and ventilator status.; Specificity of the "Confusion Assessment Method for the ICU (CAM-ICU)", the "Intensive Care DELIRIUM Screening Checklist (ICDSC)" and the "Nursing DELIRIUM Screening Scale" regarding sedation and ventilator status.; Calculation and Analysis of the positive predictive values of the assessed DELIRIUM-screening scales.; Incidence of DELIRIUM; Incidence of Subsyndromale DELIRIUM (SSD); Analgesia; Ventilator status; Administered neuroleptics, cumulative; Administered analgesics, cumulative; Administered sedatives, cumulative; Severity of illness; Antibiotics/infections; ICU length of stay; Duration of mechanical ventilation; Discharge mode; 28-day mortality; Specificity of the "Confusion Assessment Method for the ICU (CAM-ICU)", the "Intensive Care DELIRIUM Screening Checklist (ICDSC)" and the "Nursing DELIRIUM Screening Scale" regarding analgesia.; Sensitivity of the "Confusion Assessment Method for the ICU (CAM-ICU)", the "Intensive Care DELIRIUM Screening Checklist (ICDSC)" and the "Nursing DELIRIUM Screening Scale" regarding analgesia. |
|
16 |
Recruiting
|
Dexmedetomidine on Postoperative DELIRIUM and Quality of Recovery in Geriatric Patients
Condition: |
DELIRIUM, Postoperative |
Interventions: |
Drug: Placebo; Drug: Dexmedetomidine |
Outcome Measures: |
Postoperative DELIRIUM; Length of PACU stay; hemodynamic parameters; incidence of postoperative nausea and vomiting; quality of recovery determined by QOR40 and Postoperative Quality Recovery Scale (PQRS); Postoperative Stroke |
|
17 |
Recruiting
|
Prevention of DELIRIUM With Light in the Intensive Care Unit
Condition: |
DELIRIUM |
Intervention: |
Other: Circadian light |
Outcome Measures: |
Prevalence of DELIRIUM; DELIRIUM prevalence; Severity of DELIRIUM; Duration of DELIRIUM; Prevalence of subsyndromal DELIRIUM (SSD); Severity of anxiety; Cognitive Dysfunction; Post-Traumatic Stress Disorder (PTSD); Sleep quality; ICU length of stay; Duration of mechanical ventilation; Hospital length of stay; Level of sedation; Pain level; Amount of administered opioids; Amount of administered benzodiazepines; Amount of administered sedatives; Amount of administered antipsychotics; Mortality; Light levels (lux) Light levels (lux); Light frequencies; Noise levels (decibel) |
|
18 |
Unknown †
|
Validating a DELIRIUM Prediction Model for Critically Ill Patients
Condition: |
DELIRIUM |
Intervention: |
|
Outcome Measures: |
DELIRIUM; markers of inflammation |
|
19 |
Recruiting
|
Cerebral Blood Flow During CPB During Cardiac Surgery and the Presence of Post op DELIRIUM
Condition: |
DELIRIUM |
Intervention: |
|
Outcome Measures: |
To evaluate whether rSO2 and/or CBF during CPB is lower in patients who experience DELIRIUM within three days after cardiac surgery compared with patients without DELIRIUM; recovery pattern of rSO2 |
|
20 |
Recruiting
|
4-question "RACY" DELIRIUM Screening Tool Validation Study
Condition: |
DELIRIUM |
Intervention: |
Other: RACY test |
Outcome Measures: |
Diagnostic accuracy (Sensitivity, specificity, likelihood ratios) of the "RACY" DELIRIUM screening tool; 12-month cognitive outcomes in patients <50 years; Measurement of IL-6, IL-2, TNF-alpha, IFN-gamma, IGF-1, MCP-1, and hsCRP |
|